FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022103281> ?p ?o ?g. }

• W2022103281 endingPage "e87103" @default.
• W2022103281 startingPage "e87103" @default.
• W2022103281 abstract "Background The potential prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabine-based chemotherapy is variably reported. Objective The objective of this study was to conduct a systematic review of literature evaluating human equilibrative nucleoside transporter1 expression as a prognostic factor in pancreatic cancer receiving gemcitabine-based chemotherapy and to conduct a subsequent meta-analysis to quantify the overall prognostic effect. Methods Related studies were identified and evaluated for quality through multiple search strategies. Only studies analyzing pancreatic cancer receiving gemcitabine-based chemotherapy were eligible for inclusion. Data were collected from studies comparing overall, disease-free and progression-free survival (OS, DFS and PFS) in patients with low human equilibrative nucleoside transporter1 levels and those having high levels. The hazard ratio (HR) and its 95% confidence interval (95%CI) were used to assess the strength of associations. Hazard ratios greater than 1 reflect adverse survival associated with low human equilibrative nucleoside transporter1 levels. Results A total of 12 studies (n = 875) were involved in this meta-analysis (12 for OS, 5 for DFS, 3 for PFS). For overall and disease-free survival, the pooled HRs of human equilibrative nucleoside transporter1 were significant at 2.93 (95% confidence interval [95% CI], 2.37–3.64) and 2.67 (95% CI, 1.87–3.81), respectively. For progression-free survival, the pooled HR in higher human equilibrative nucleoside transporter1 expression in pancreatic cancer receiving gemcitabine-based chemotherapy was 2.76 (95% CI, 1.76–4.34). No evidence of significant heterogeneity or publication bias was seen in any of these studies. Conclusion These results support the case for a low human equilibrative nucleoside transporter1 level representing a significant and reproducible marker of adverse prognosis in pancreatic cancer receiving gemcitabine-based chemotherapy." @default.
• W2022103281 created "2016-06-24" @default.
• W2022103281 creator A5010478603 @default.
• W2022103281 creator A5024819895 @default.
• W2022103281 creator A5028960993 @default.
• W2022103281 creator A5044692680 @default.
• W2022103281 creator A5059550582 @default.
• W2022103281 creator A5065882373 @default.
• W2022103281 creator A5066796679 @default.
• W2022103281 creator A5070538645 @default.
• W2022103281 date "2014-01-27" @default.
• W2022103281 modified "2023-10-14" @default.
• W2022103281 title "Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis" @default.
• W2022103281 cites W1931508686 @default.
• W2022103281 cites W1934807066 @default.
• W2022103281 cites W1966838279 @default.
• W2022103281 cites W1968323734 @default.
• W2022103281 cites W1976571379 @default.
• W2022103281 cites W1979423827 @default.
• W2022103281 cites W2012176955 @default.
• W2022103281 cites W2030873172 @default.
• W2022103281 cites W2048149859 @default.
• W2022103281 cites W2048312581 @default.
• W2022103281 cites W2051111830 @default.
• W2022103281 cites W2054186497 @default.
• W2022103281 cites W2061007461 @default.
• W2022103281 cites W2061797905 @default.
• W2022103281 cites W2063226474 @default.
• W2022103281 cites W2075642745 @default.
• W2022103281 cites W2097642908 @default.
• W2022103281 cites W2101017561 @default.
• W2022103281 cites W2118513443 @default.
• W2022103281 cites W2118649578 @default.
• W2022103281 cites W2126658009 @default.
• W2022103281 cites W2129051737 @default.
• W2022103281 cites W2129197203 @default.
• W2022103281 cites W2131025996 @default.
• W2022103281 cites W2131555383 @default.
• W2022103281 cites W2138089399 @default.
• W2022103281 cites W2138582833 @default.
• W2022103281 cites W2140178932 @default.
• W2022103281 cites W2150415957 @default.
• W2022103281 cites W2157632766 @default.
• W2022103281 cites W2157823046 @default.
• W2022103281 cites W2158134441 @default.
• W2022103281 cites W2163192772 @default.
• W2022103281 cites W2204134524 @default.
• W2022103281 cites W3144138202 @default.
• W2022103281 doi "https://doi.org/10.1371/journal.pone.0087103" @default.
• W2022103281 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3903621" @default.
• W2022103281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24475233" @default.
• W2022103281 hasPublicationYear "2014" @default.
• W2022103281 type Work @default.
• W2022103281 sameAs 2022103281 @default.
• W2022103281 citedByCount "17" @default.
• W2022103281 countsByYear W20221032812014 @default.
• W2022103281 countsByYear W20221032812015 @default.
• W2022103281 countsByYear W20221032812016 @default.
• W2022103281 countsByYear W20221032812017 @default.
• W2022103281 countsByYear W20221032812018 @default.
• W2022103281 countsByYear W20221032812019 @default.
• W2022103281 countsByYear W20221032812020 @default.
• W2022103281 countsByYear W20221032812021 @default.
• W2022103281 countsByYear W20221032812022 @default.
• W2022103281 countsByYear W20221032812023 @default.
• W2022103281 crossrefType "journal-article" @default.
• W2022103281 hasAuthorship W2022103281A5010478603 @default.
• W2022103281 hasAuthorship W2022103281A5024819895 @default.
• W2022103281 hasAuthorship W2022103281A5028960993 @default.
• W2022103281 hasAuthorship W2022103281A5044692680 @default.
• W2022103281 hasAuthorship W2022103281A5059550582 @default.
• W2022103281 hasAuthorship W2022103281A5065882373 @default.
• W2022103281 hasAuthorship W2022103281A5066796679 @default.
• W2022103281 hasAuthorship W2022103281A5070538645 @default.
• W2022103281 hasBestOaLocation W20221032811 @default.
• W2022103281 hasConcept C121608353 @default.
• W2022103281 hasConcept C126322002 @default.
• W2022103281 hasConcept C143998085 @default.
• W2022103281 hasConcept C207103383 @default.
• W2022103281 hasConcept C2776694085 @default.
• W2022103281 hasConcept C2780210213 @default.
• W2022103281 hasConcept C2780258809 @default.
• W2022103281 hasConcept C44249647 @default.
• W2022103281 hasConcept C71924100 @default.
• W2022103281 hasConceptScore W2022103281C121608353 @default.
• W2022103281 hasConceptScore W2022103281C126322002 @default.
• W2022103281 hasConceptScore W2022103281C143998085 @default.
• W2022103281 hasConceptScore W2022103281C207103383 @default.
• W2022103281 hasConceptScore W2022103281C2776694085 @default.
• W2022103281 hasConceptScore W2022103281C2780210213 @default.
• W2022103281 hasConceptScore W2022103281C2780258809 @default.
• W2022103281 hasConceptScore W2022103281C44249647 @default.
• W2022103281 hasConceptScore W2022103281C71924100 @default.
• W2022103281 hasIssue "1" @default.
• W2022103281 hasLocation W20221032811 @default.
• W2022103281 hasLocation W20221032812 @default.
• W2022103281 hasLocation W20221032813 @default.
• W2022103281 hasLocation W20221032814 @default.

• next